Patents by Inventor Peter Schwarz

Peter Schwarz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130252263
    Abstract: The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo. The invention also relates to methods of using various animal models which demonstrate ADAMTS13 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma.
    Type: Application
    Filed: March 12, 2013
    Publication date: September 26, 2013
    Applicants: BAXTER HEALTHCARE SA, BAXTER INTERNATIONAL INC.
    Inventors: Katalin Varadi, Hanspeter Rottensteiner, Peter Turecek, Hans-Peter Schwarz, Jutta Schreiner
  • Patent number: 8529807
    Abstract: The present invention relates to methods by which to produce sheet-like, wafer-like or film-like forms of drugs, confectionary, other food, cosmetics and the like for oral application or intake. The present invention is more particularly directed to the thermal treatment of carrier materials used in the production of such sheet-like, wafer-like or film-like forms. The thermal treatment removes contaminating or undesired substances from the carrier material.
    Type: Grant
    Filed: January 14, 2003
    Date of Patent: September 10, 2013
    Assignee: LTS Lohmann Therapie-Systeme AG
    Inventors: Detlev Neuland, Wolfgang Schaefer, Peter Schwarz
  • Patent number: 8415114
    Abstract: The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo. The invention also relates to methods of using various animal models which demonstrate ADAMTS13 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma.
    Type: Grant
    Filed: December 3, 2009
    Date of Patent: April 9, 2013
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Katalin Varadi, Hanspeter Rottensteiner, Peter Turecek, Hans-Peter Schwarz, Jutta Schreiner
  • Patent number: 8409082
    Abstract: A video endoscope has an endoscope part having a central image signal conductor, at least one optical waveguide, and a light supplying part which can be coupled to a proximal end of said endoscope part. The light supplying part has a central image signal conductor connection at a distal end thereof, and a light supply arranged coaxially around said central image signal conductor connection. The light supply has a plurality of light-emitting elements, each of said light-emitting elements can be supplied by means of a switchable semiconductor light source. Position sensors are arranged in an area of said light-emitting elements, and position indicators are arranged in an area of said optical waveguide. A position of said position indicators can be detected by said position sensors when said endoscope part and said light supplying part are coupled. Based on a detection of said position indicator, at least those light-emitting elements lying opposite to said optical waveguide are activated.
    Type: Grant
    Filed: July 7, 2009
    Date of Patent: April 2, 2013
    Assignee: Karl Storz GmbH & Co. KG
    Inventors: Klaus-Martin Irion, Peter Schwarz
  • Publication number: 20130058961
    Abstract: The present invention provides methods for reducing the amidolytic and anti-complement activity (ACA) content of an immunoglobulin composition through the use of cation exchange chromatography. In a specific embodiment, the invention provides methods for reducing the Factor XI and/or Factor XIa and/or ACA content of an immunoglobulin composition by collecting the leading portion of a cation exchange eluate. The present invention also provides immunoglobulin composition having reduced levels of amidolytic activity, Factor XI, and/or Factor XIa, and/or ACA content.
    Type: Application
    Filed: August 27, 2012
    Publication date: March 7, 2013
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventors: Wolfgang Teschner, Harald Arno Butterweck, Bernhard Kölbl, Lucia Hofbauer, Hans-Peter Schwarz
  • Publication number: 20130050684
    Abstract: An apparatus for measuring optical properties of transparent materials with a first illumination device which illuminates the material to be investigated along a pre-set illumination path with a pre-set radiation, with a radiation recording space which records radiation passed on by the material to be investigated. The radiation recording space is arranged so that radiation emitted by the first illumination device first strikes the material and then at least for a time an inner wall of the radiation recording space. A radiation detector device is arranged to record radiation reflected and/or scattered essentially only from the inner wall. A second illumination device suitable for emitting modulated radiation also illuminates the inner wall.
    Type: Application
    Filed: August 9, 2012
    Publication date: February 28, 2013
    Inventors: Severin Wimmer, Peter Schwarz
  • Publication number: 20130052672
    Abstract: The invention provides a kit for measuring the thrombin generation in a sample of a patient's blood or plasma, or in a sample of clotting factors. The kit contains lyophilized tissue factor/phospholipid-complex and a lyophilized mixture containing a thrombin-substrate and CaCl2. The invention also provides processes for preparing the reagents for the kit. The kit can be used in a method for measuring the thrombin generation in a sample, wherein it is possible to detect changes in thrombin generation kinetics, for example after administration of inhibitor bypassing agents to a patient who has developed inhibitors to an exogenous clotting factor such as Factor VIII.
    Type: Application
    Filed: June 29, 2012
    Publication date: February 28, 2013
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventors: Katalin Varadi, Peter Turecek, Brigitte Keil, Sylvia Peyrer-Heimstaett, Hans-Peter Schwarz
  • Publication number: 20130043383
    Abstract: Disclosed herein are methods of determining polydispersity (PDI) and molecular mass distribution (MMD) of reactive PEG samples using mass spectrometry. More specifically, a mass spectrometry method called GEMMA is used to determine PDI and MMD of PEG samples which provides more accurate measurements for high molecular weight PEG samples than prior known MALDI-TOF analysis.
    Type: Application
    Filed: March 21, 2012
    Publication date: February 21, 2013
    Applicants: BAXTER HEALTHCARE S. A., TECHNISCHE UNIVERSITAET WIEN, BAXTER INTERNATIONAL INC.
    Inventors: Jasmin Kemptner, Martina Marchetti-Deschmann, Juergen Siekmann, Peter Turecek, Hans-Peter Schwarz, Guenter Allmaier
  • Patent number: 8377375
    Abstract: The present invention relates to a method for determining an effective dose of monochromatic or polychromatic light from one or more light sources to inactivate microorganisms present in a biological fluid, preferably a non-transparent fluid. Moreover, there is provided a method for the inactivation of microorganism in a biological fluid in a flow-through-reactor. Moreover, the invention advantageously provides a flow-through-reactor with one or more thermostated light sources. The invention further provides a method of controlling the light sum dose of monochromatic or polychromatic light emitted from one or more light sources to effectively inactivate microorganisms present in a biological fluid in a batch reactor.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: February 19, 2013
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Heinz Anderle, Peter Matthiessen, Hans-Peter Schwarz, Peter Turecek, Thomas Kreil, Daniel R. Boggs
  • Publication number: 20130027545
    Abstract: Radiation is irradiated by an irradiation device at a pre-set angle of incidence with respect to the surface onto the surface to be investigated, and the radiation scattered and/or reflected by this surface arrives at a radiation detector device arranged at a pre-set detection angle with respect to the surface and having an image-recording unit which records black-and-white images, wherein this radiation detector device permits a spatially resolved detection of the radiation reaching it. The irradiation device directs radiation in a first wavelength range onto the surface and the image-recording unit records a first spatially resolved image of this radiation scattered and/or reflected from the surface and the irradiation device directs radiation in a second wavelength range onto the surface and the image-recording unit records a second spatially resolved image of this radiation scattered and/or reflected from the surface.
    Type: Application
    Filed: June 29, 2012
    Publication date: January 31, 2013
    Inventors: Peter Schwarz, Uwe Sperling
  • Patent number: 8355141
    Abstract: A method for optical investigation of textured surfaces involves the steps of irradiation of radiation onto the surface to be investigated; reception of an image from at least part of the radiation irradiated onto the surface and reflected by the surface; location-resolved evaluation of the image recorded and determination of at least one value K which is characteristic of this image. A parameter G which is characteristic of the surface is determined while using the characteristic value K and while using at least one further property E known beforehand or determined of the surface.
    Type: Grant
    Filed: July 9, 2010
    Date of Patent: January 15, 2013
    Assignee: BYK-Gardner GmbH
    Inventors: Peter Schwarz, Uwe Sperling
  • Publication number: 20130012777
    Abstract: Endoscopic arrangement comprising a first distal end, an imaging device arranged at the first distal end, a first proximal end for connection to a supply unit, a data transmission element embodied as a light guide and having a second distal end and a second proximal end, and comprising an electro-optical converter, wherein the electro-optical converter is configured to convert digital data generated by the imaging device into an optical signal, wherein the data transmission element at its second distal end is optically coupled to the electro-optical converter for coupling the optical signal into the data transmission element, wherein the imaging device comprises at least two data outputs each having a digital output signal, and wherein a first signal converter is provided between the imaging device and the electro-optical converter for combining the digital output signals into a digital combined output signal.
    Type: Application
    Filed: July 3, 2012
    Publication date: January 10, 2013
    Inventors: Eckhart Baum, Klaus-Martin Irion, Peter Schwarz, Daniel Efinger
  • Patent number: 8343748
    Abstract: Recombinant truncated human furin was expressed in CHO cells and concentrated approximately 50-fold by ultrafiltration and diafiltration. The concentrate was purified by column chromatography on CAPTO MMC™ (mixed cation exchange/hydrophobic interaction gel) resulting in a 30-50 fold purification factor and a yield of at least 60%. The at least 20% pure preparation obtained after CAPTO MMC™ (mixed cation exchange/hydrophobic interaction gel) chromatography had already a purification degree allowing on-column maturation of pro-VWF. Then an additional Arginine Sepharose chromatography purification was carried out. This two column process for purification of truncated human furin resulted in an almost pure furin preparation with a specific activity of approximately 290,000 U furin/mg protein and a yield of about 50%.
    Type: Grant
    Filed: May 21, 2008
    Date of Patent: January 1, 2013
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Peter Matthiessen, Stefan Romeder-Finger, Peter Turecek, Hans-Peter Schwarz
  • Publication number: 20120329072
    Abstract: Disclosed herein are methods, systems and kits to measure the presence and/or activity of recombinant polypeptides comprising a modification.
    Type: Application
    Filed: May 18, 2012
    Publication date: December 27, 2012
    Inventors: Alfred Weber, Andrea Engelmaier, Hans-Peter Schwarz
  • Publication number: 20120322737
    Abstract: The present invention provides novel methods of increasing the survival of a coagulation protein by inhibiting the interaction with a clearance receptor. The invention also provides methods of preparing compositions that inhibit coagulation protein clearance receptors. Conjugated coagulation proteins, including compositions and formulations thereof, are also provided by the present invention.
    Type: Application
    Filed: April 20, 2012
    Publication date: December 20, 2012
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventors: Hans-Peter Schwarz, Peter Turecek
  • Publication number: 20120322090
    Abstract: The present invention relates to a method for the measurement of active alpha1-proteinase inhibitor (A1PI) in a sample, comprising the steps of binding elastase to a solid support, letting the A1PI contained in the sample bind to the solid phase-bound elastase, and detecting solid phase-bound A1PI with a detection reagent.
    Type: Application
    Filed: April 25, 2012
    Publication date: December 20, 2012
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventors: Alfred Weber, Andrea Engelmaier, Hans-Peter Schwarz
  • Publication number: 20120309021
    Abstract: The present invention provides analytical methods for detecting anti-polymer antibody in an individual. The methods involve contacting a sample from the individual with a water soluble polymer-modified carrier and detecting binding of antibody to the water soluble polymer on the water soluble polymer-modified carrier wherein binding is indicative of the presence of antibody to the water polymer-modified polypeptide. Antibody may be detected to water soluble polymers such as polyethylene glycol, polysialic acid, dextran, hydroxyalkyl starch, or hydroxyethyl starch. When antibody to the water soluble polymer polyethylene glycol is to be detected, the carrier is modified with a non-linear polyethylene glycol derivative.
    Type: Application
    Filed: June 6, 2012
    Publication date: December 6, 2012
    Applicant: BAXTER INTERNATIONAL INC.
    Inventors: Christian Lubich, Juergen Siekmann, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich
  • Patent number: 8315974
    Abstract: A computer network architecture for making procurement-related information that has been generated on a transaction level available to data warehousing techniques is described. The network includes a transaction processing layer with at least one accounting component with a general ledger data base for centrally storing information contained in accounted-related data sets, a data warehousing layer and an additional data sourcing layer. A duplicator receives the data sets that will be or have been stored in the general ledger data base and delivers duplicates of those data sets that fulfil a predefined criteria in a procurement context. A source data base stores the duplicated data sets on a data line level. An extractor of the data sourcing layer interfaces with the data warehousing layer and selectively moves data contained in data lines or sets of data lines from the source data base to the data warehousing layer.
    Type: Grant
    Filed: January 16, 2009
    Date of Patent: November 20, 2012
    Assignee: SAP AG
    Inventors: Karsten Bruening, Georg Dopf, Stefan Gauger, Danny Pannicke, Rolf Schumann, Peter Schwarz, Juergen Alfred Seyfried, Andreas Reccius
  • Patent number: 8304524
    Abstract: The present invention provides compositions and pharmaceutical formulations of Factor H derived from plasma. Also provided are methods for the manufacture of the Factor H compositions and formulations, as well as methods for the treatment of diseases associated with Factor H dysfunction.
    Type: Grant
    Filed: July 23, 2010
    Date of Patent: November 6, 2012
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Shawn F. Bairstow, Richard Johnson, Sindhu Ramachandran, Ruth Madlener, Wolfgang Teschner, Hans-Peter Schwarz
  • Publication number: 20120248333
    Abstract: A diagnosis device having an illumination system configured to produce white light along an illumination path, an observation system for observing the target region in a white-light and fluorescence mode, the observation system having an observation path having at least one first image sensor for receiving a white-light image and at least one second image sensor for receiving a fluorescence image, an observation spectral filter in the observation path are configured such that light in the spectral range of the fluorescence can be fed to the second image sensor while light in the spectral ranges outside of the fluorescence is blocked. An illumination spectral filter is arranged in the illumination path and having a characteristic of the observation spectral filter such that the target region is illuminated with the whole spectral range of the white light with the exception of the spectral range of the fluorescence to be observed.
    Type: Application
    Filed: March 26, 2012
    Publication date: October 4, 2012
    Inventors: Johannes Fallert, Peter Schwarz, Werner Goebel, Andre Ehrhardt, Klaus-Martin Irion